SEARCH

SEARCH BY CITATION

References

  • 1
    Bergqvist D, Benoni G, Björgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
  • 2
    Planes A, Vochelle N, Mazas F, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224 8.
  • 3
    Dahl O, Andreasen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26 31.
  • 4
    Lassen M, Borris L, Andersen BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular weight heparin (Dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res 1998;89:281 7.
  • 5
    Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996;93:1548 52.
  • 6
    Dunn CJ & Goa KL. Enoxaparin—A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics 1996;10 (2):179 90.
  • 7
    Heaton D & Pearce M. Low molecular weight versus unfractionated heparin—A clinical and economic appraisal. Pharmacoeconomics 1995;8(2):91 9.
  • 8
    Harrison J, Warwick D, Coast J. Economics of thromboprophylaxis in total hip replacement surgery. Pharmacoeconomics 1997;12:30 41.
  • 9
    Lindmarker P & Holmström A. Use of low molecular weight heparin (dalteparin), once daily, for treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395 401.
  • 10
    Menzin J, Richner R, Huse D, et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271 5.
  • 11
    Menzin J, Colditz GA, Regan MM, et al. Cost effectiveness of enoxaparin vs. low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155:757 64.
  • 12
    Borris LC, Lassen M, Jensen HP, et al. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery—clinical and economic considerations. Intern J Clin Pharm Ther 1994;32:262 8.
  • 13
    Mol WEM & Egberts TCG. Prophylaxis for venous thromboembolism in hip fracture surgery—Total costs and cost effectiveness in The Netherlands. Pharmacoeconomics 1994;5 (1):48 55.
  • 14
    Drummond M, Aristides M, Davies L, et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81: 1742 6.
  • 15
    O'brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;334:724 5.
  • 16
    Statistical Yearbook of Sweden 1997, table 55. Stockholm: Statistics Sweden.
  • 17
    Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677 81.
  • 18
    Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med 1992;232:155 60.
  • 19
    Detorunay B, Planes A, Vochelle N, et al. Cost–effectiveness of low–molecular–weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998;13:81 9.